Muramyldipeptide derivatives and influenza vaccine comprising the derivatives
US5292506A · kind A · utility
4Cited by
1References
15Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Oct 28, 1991 |
| Grant date | Mar 8, 1994 |
| Priority date | — |
| Expiry date | Oct 28, 2011 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY10S424/812
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Novel muramyldipeptide derivatives such as [6-0-(2-tetradecylhexadecanoyl)-N-acetylmuramoyl]-L-alanyl-D-glutamamide and [6-0-(2-tetradecylhexadecanoyl)-N-acetylmuramoyl]-L-alanyl-N -methyl-D-glutamamide are provided. The muramyldipeptide derivatives are excellent compound as an adjuvant or a constituting component of virosome vaccine. An influenza vaccine comprises a complex of the muramyldipeptide derivative and an influenza virus antigen. The influenza vaccine has excellent antibody-producing capacity and safety.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.